REG - Haleon PLC - Board Change

HALEONAnnouncement

25/02/2025 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250225:nRSY4085Ya&default-theme=true

RNS Number : 4085Y  Haleon PLC  25 February 2025

 

 

Haleon plc: Board Change

 

25 February 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces the following change to the Board.

 

Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 10%,
and in line with the Pfizer Relationship Agreement with Haleon plc, Bryan
Supran, Non-Executive Director and representative of Pfizer Inc., stepped down
from the Board on 25 February 2025.

 

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would
like to thank Bryan for his contributions to the Board's discussions and for
being part of the Haleon journey from the initial joint-venture in 2019
through demerger to today. We wish him all the very best for the future."

 

The Company confirms that there is no further information to be disclosed
under the requirements of UKLR 6.4.6R.

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPKPBBBBKDDBB